Zacks: Brokerages Expect Kala Pharmaceuticals, Inc. (NASDAQ:KALA) Will Post Earnings of -$0.38 Per Share - Defense World - Financial Daily News Site

Zacks: Brokerages Expect Kala Pharmaceuticals, Inc. (NASDAQ:KALA) Will Post Earnings of -$0.38 Per Share – Defense World


Brokerages forecast that Kala Pharmaceuticals, Inc. (NASDAQ:KALA – Get Rating) will report earnings per share of ($0.38) for the current fiscal quarter, Zacks Investment Research reports. Six analysts have made estimates for Kala Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.43) and the highest estimate coming in at ($0.30). Kala Pharmaceuticals reported earnings of ($0.57) per share during the same quarter last year, which would suggest a positive year over year growth rate of 33.3%. The business is scheduled to report its next earnings results on Monday, January 1st.

According to Zacks, analysts expect that Kala Pharmaceuticals will report full year earnings of ($1.33) per share for the current year, with EPS estimates ranging from ($1.45) to ($1.10). For the next fiscal year, analysts anticipate that the firm will post earnings of ($0.85) per share, with EPS estimates ranging from ($1.14) to ($0.70). Zacks Investment Research’s earnings per share averages are an average based on a survey of research analysts that that provide coverage for Kala Pharmaceuticals.

Kala Pharmaceuticals (NASDAQ:KALA – Get Rating) last posted its earnings results on Monday, May 16th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.09). Kala Pharmaceuticals had a negative return on equity of 369.16% and a negative net margin of 1,552.90%. During the same quarter last year, the firm posted ($0.49) EPS.

KALA has been the topic of several recent analyst reports. JPMorgan Chase & Co. downgraded Kala Pharmaceuticals from a “neutral” rating to an “underweight” rating and set a $1.50 price target on the stock. in a report on Wednesday, March 30th. Zacks Investment Research raised Kala Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, February 16th. HC Wainwright dropped their target price on Kala Pharmaceuticals from $5.00 to $4.00 and set a “buy” rating on the stock in a research report on Tuesday, May 24th. Northland Securities dropped their target price on Kala Pharmaceuticals from $6.00 to $4.00 and set an “outperform” rating on the stock in a research report on Wednesday, March 30th. Finally, Wedbush lowered their price objective on Kala Pharmaceuticals from $6.00 to $3.00 and set a “na” rating for the company in a research report on Tuesday, May 17th. One analyst has rated the stock with a sell rating, one has given a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $3.13.

In other news, major shareholder Ra Capital Management, L.P. sold 1,434,509 shares of the business’s stock in a transaction that occurred on Wednesday, May 25th. The stock was sold at an average price of $0.42, for a total transaction of $602,493.78. Following the transaction, the insider now directly owns 8,045,299 shares in the company, valued at approximately $3,379,025.58. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 30.55% of the company’s stock.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in KALA. BNP Paribas Arbitrage SA increased its holdings in Kala Pharmaceuticals by 366.1% in the third quarter. BNP Paribas Arbitrage SA now owns 10,670 shares of the company’s stock valued at $28,000 after buying an additional 8,381 shares during the last quarter. Bank of New York Mellon Corp increased its holdings in Kala Pharmaceuticals by 5.4% in the third quarter. Bank of New York Mellon Corp now owns 188,931 shares of the company’s stock valued at $495,000 after buying an additional 9,642 shares in the last quarter. Barclays PLC increased its holdings in Kala Pharmaceuticals by 43.3% in the third quarter. Barclays PLC now owns 34,053 shares of the company’s stock valued at $88,000 after buying an additional 10,287 shares in the last quarter. Oppenheimer & Co. Inc. increased its holdings in Kala Pharmaceuticals by 33.6% in the third quarter. Oppenheimer & Co. Inc. now owns 41,000 shares of the company’s stock valued at $107,000 after buying an additional 10,300 shares in the last quarter. Finally, Virtu Financial LLC increased its stake in shares of Kala Pharmaceuticals by 11.3% during the 1st quarter. Virtu Financial LLC now owns 140,511 shares of the company’s stock worth $194,000 after purchasing an additional 14,280 shares in the last quarter. Hedge funds and other institutional investors own 52.81% of the company’s stock.

Shares of NASDAQ:KALA traded up $0.02 during trading on Friday, reaching $0.38. 3,272,979 shares of the stock were exchanged, compared to its average volume of 2,224,404. The stock has a fifty day moving average of $0.79 and a two-hundred day moving average of $1.06. Kala Pharmaceuticals has a 1-year low of $0.34 and a 1-year high of $6.77. The firm has a market cap of $27.58 million, a price-to-earnings ratio of -0.18 and a beta of 1.00. The company has a debt-to-equity ratio of 5.04, a current ratio of 3.00 and a quick ratio of 2.68.

About Kala Pharmaceuticals (Get Rating)

Kala Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary mucus penetrating particles technology for the treatment of eye diseases. The company’s product candidates include KPI-012, which is in clinical development stage for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery.

Featured Articles

Get a free copy of the Zacks research report on Kala Pharmaceuticals (KALA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Kala Pharmaceuticals (NASDAQ:KALA)



Receive News & Ratings for Kala Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Kala Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.

Tags: #Zacks #Brokerages #Expect #Kala #Pharmaceuticals #NASDAQKALA #Post #Earnings #Share #Defense #World

Leave a Comment